Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.42 |
| ▸ | ORAI2 | Q96SN7 | 3/20 | 0.42 |
| ▸ | ORAI3 | Q9BRQ5 | 3/20 | 0.42 |
| ▸ | TRPV6 | Q9H1D0 | 3/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672441 | 0.82 | ORAI1 (0.46) | ORAI1ORAI2ORAI3TRPV6CA4 | |
| SCHEMBL28664851 | 0.80 | TRPV6 (0.44) | ORAI1ORAI2ORAI3TRPV6CA4 | |
| SCHEMBL651370 | 0.78 | ORAI1 (0.42) | ORAI1ORAI2ORAI3TRPV6CA4 | |
| SCHEMBL20916961 | 0.78 | LMNA (0.54) | ORAI1ORAI2ORAI3TRPV6CA4 | |
| SCHEMBL384014 | 0.78 | ORAI1 (0.42) | ORAI1ORAI2ORAI3TRPV6CA4 | |
| SCHEMBL28532508 | 0.78 | THRB (0.42) | ORAI1ORAI2ORAI3TRPV6CA4 | |
| SCHEMBL27008267 | 0.77 | TRPV6 (0.41) | ORAI1ORAI2ORAI3TRPV6CA4 | |
| SCHEMBL28524847 | 0.76 | ELANE (0.44) | ORAI1ORAI2ORAI3TRPV6CA4 | |
| SCHEMBL1237453 | 0.75 | KMT2A (0.42) | ORAI1ORAI2ORAI3TRPV6CA4 | |
| SCHEMBL56442 | 0.75 | ORAI1 (0.39) | ORAI1ORAI2ORAI3TRPV6CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119081323-A | Wear-resistant impact-resistant high polymer floor and preparation process thereof | 洁玛新材料股份有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-118063863-A | Double-functional nano-particle for rapidly detecting sterilizing bacteria and preparation method and application thereof | 江苏省农业科学院 | 2024-05-24 | — | — | CN | claimed |
| EP-4634184-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | Crossfire Oncology Holding B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| CN-119081323-A | Wear-resistant impact-resistant high polymer floor and preparation process thereof | 洁玛新材料股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| WO-2024126617-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-06-20 | — | — | WO | disclosed |
| CN-118063863-A | Double-functional nano-particle for rapidly detecting sterilizing bacteria and preparation method and application thereof | 江苏省农业科学院 | 2024-05-24 | — | — | CN | disclosed |
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-115812085-A | Dynamic covalent hydrogels, precursors thereof and uses thereof | 国家科学研究中心 | 2023-03-17 | — | — | CN | disclosed |
| WO-2022212194-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | disclosed |
| WO-2012024615-A1 | NICOTINIC RECEPTOR COMPOUNDS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011149950-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2379561-A2 | MLK INHIBITORS AND METHODS OF USE | University Of Rochester (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2212333-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | Wyeth LLC (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2010068483-A2 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2010-06-17 | — | — | WO | disclosed |
| EP-2124913-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009052145-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | ORAI1 4116/4885ORAI2 3334/4885ORAI3 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.